ensysce biosciences, san diego, ca, is an integrated drug delivery company for both small and large molecules. to overcome the major problem of non-medical use of opioid products, ensysce is using its prodrug technology to improve abuse deterrent properties. the tap bio-md™ abuse deterrent and mpar™ overdose resistant pain platforms, with worldwide intellectual patent protection, eliminate the ability to abuse opioid products by the non-oral route. this abuse is the fastest growing drug problem in the u.s. and it leads to billions in healthcare costs annually. for additional information about ensysce biosciences please visit www.ensysce.com.

Company profile
Ticker
ENSC, ENSCW
Exchange
Website
CEO
Daniel B. Silvers
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Leisure Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Covistat, Inc. • EBI OpCo, Inc. • EBI Operating, Inc. ...
ENSC stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
28 Aug 23
8-K
Ensysce Biosciences Reports Second Quarter 2023 Financial Results
11 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
DEFA14A
Additional proxy soliciting materials
13 Jul 23
DEF 14A
Definitive proxy
13 Jul 23
8-K
Other Events
13 Jun 23
8-K
Other Events
2 Jun 23
POS EX
Additional exhibits for listing
17 May 23
AW
Withdrawal of amendment
17 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
Latest ownership filings
SC 13D/A
GOWER BOB G
18 Jul 23
4
BOB G GOWER
6 Mar 23
4
BOB G GOWER
2 Mar 23
SC 13G/A
HG Vora Capital Management, LLC
14 Feb 23
SC 13G/A
CVI Investments, Inc.
14 Feb 23
SC 13G
Lincoln Park Capital Fund, LLC
7 Feb 23
4
BOB G GOWER
1 Feb 23
SC 13G
CVI Investments, Inc.
16 Dec 22
SC 13D/A
Silvers Daniel B.
7 Jul 22
4
William H Chang
27 Jun 22
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.83 mm | 3.83 mm | 3.83 mm | 3.83 mm | 3.83 mm | 3.83 mm |
Cash burn (monthly) | (no burn) | (no burn) | 764.65 k | 1.43 mm | 1.04 mm | 1.39 mm |
Cash used (since last report) | n/a | n/a | 2.16 mm | 4.05 mm | 2.92 mm | 3.93 mm |
Cash remaining | n/a | n/a | 1.67 mm | -218.65 k | 906.30 k | -102.53 k |
Runway (months of cash) | n/a | n/a | 2.2 | -0.2 | 0.9 | -0.1 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 4 |
Closed positions | 5 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 712.73 mm |
Total shares | 6.99 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Silvers Daniel B. | 2.88 mm | $2.50 mm |
Hydra LAC | 1.87 mm | $27.07 mm |
Lincoln Park Capital Fund | 1.50 mm | $1.17 mm |
CVI Investments | 336.87 k | $0.00 |
Sabby Management | 322.30 k | $580.14 mm |
Anson Funds Management | 36.26 k | $65.27 mm |
Gsa Capital Partners | 17.55 k | $32.00 k |
Vanguard | 15.42 k | $27.75 mm |
Tower Research Capital | 3.90 k | $7.02 mm |
BLK Blackrock | 975.00 | $1.76 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Mar 23 | Bob G Gower | Common Stock | Buy | Acquire P | No | No | 0.4883 | 90,287 | 44.09 k | 1,222,682 |
1 Mar 23 | Bob G Gower | Common Stock | Buy | Acquire P | No | No | 0.4777 | 270,000 | 128.98 k | 1,132,395 |
28 Feb 23 | Bob G Gower | Common Stock | Buy | Acquire P | No | No | 0.4883 | 109,300 | 53.37 k | 862,395 |
9 Dec 22 | Bob G Gower | Buy | Acquire P | No | No | 1.4 | 357,143 | 500.00 k | 753,095 | |
9 Dec 22 | Bob G Gower | Common Stock | Grant | Acquire A | No | No | 1.4 | 714,286 | 1.00 mm | 716,365 |
23 Jun 22 | Adam Levin | Stock Option Common Stock | Grant | Acquire A | No | No | 0.425 | 15,000 | 6.38 k | 35,000 |
23 Jun 22 | Curtis Rosebraugh | Stock Option Common Stock | Grant | Acquire A | No | No | 0.425 | 20,000 | 8.50 k | 35,000 |
News
Stocks That Hit 52-Week Lows On Thursday
21 Sep 23
Stocks That Hit 52-Week Lows On Tuesday
19 Sep 23
Ensysce Biosciences Q2 EPS $(0.98) Up From $(57.60) YoY, Sales $490.47K Up From $207.47K YoY
11 Aug 23
Ensysce Biosciences Announces IRB Approval Of Key Study Protocol
8 Aug 23
Ensysce Biosciences Announces Engagement Of Alacrita Consulting
26 Jul 23
Press releases
Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023
19 Sep 23
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies
14 Sep 23
Ensysce Presents "A New Generation of Safer Pain Treatments"
7 Sep 23
Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
5 Sep 23
Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium
14 Aug 23